Research programme: protein kinase inhibitors - Genosco

Drug Profile

Research programme: protein kinase inhibitors - Genosco

Alternative Names: EGFR inhibitors - Genosco; Epidermal growth factor receptor inhibitors - Genosco; FLT3 inhibitor - Genosco; FMS-like tyrosine kinase-3 inhibitors - Genosco; G-801; GNS-1480; LRRK2 inhibitors - Genosco; Spleen tyrosine kinase inhibitors - Genosco; SYK inhibitors - Genosco

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator Genosco
  • Developer Genosco; Yuhan
  • Class Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Fibroblast growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; LRRK2 protein inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Non-small cell lung cancer
  • Research Diffuse large B cell lymphoma; Hepatocellular carcinoma; Parkinson's disease; Peripheral T-cell lymphoma

Most Recent Events

  • 02 Sep 2016 Early research in Parkinson's disease in USA (unspecified route) before September 2016
  • 02 Sep 2016 Early research in Hepatocellular carcinoma in USA (unspecified route) before September 2016
  • 02 Sep 2016 Early research in Diffuse large B cell lymphoma in USA (unspecified route) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top